BTN3A is a prognosis marker and a promising target for Vγ9Vδ2 T cells based-immunotherapy in pancreatic ductal adenocarcinoma (PDAC)

Audrey Benyamine, Céline Loncle, Etienne Foucher, Juan-Luis Blazquez, Céline Castanian, Anne-Sophie Chretien, Mauro Modesti, Veronique Secq, Salem Chouaib, Meritxell Gironella, Elena Vila-Navarro, Giuseppe Montalto, Jean-Charles Dagorn, Nelson Dusetti, Juan Iovanna, and Daniel Olive

Introduction

Pancreatic Ductal Adenocarcinoma (PDAC) is an aggressive disease with a 5-year survival rate below 8%, for which conventional treatments have had a very limited impact. The efficacy of immunotherapy strategies in melanoma and non-small cell lung carcinoma has paved the way for their exploration in other solid tumors with poor prognosis. While the association of systemic and intra-tumoral immune status with PDAC prognosis would suggest it relevant to develop such approaches in PDAC, it is thought that the hostile tumor micro-environment of PDAC may ultimately restrain the efficacy of immunotherapy. Indeed, the poorly vascularized and fibrotic stroma of PDAC gives rise to nutrient deprivation and hypoxia which induces the selection of aggressive tumor cells together with an immunosuppressive tumor microenvironment. Novel original strategies that take into account these specificities of PDAC are therefore being actively investigated.

The PDAC micro-environment contains γδ T cells which constitute up to 75% of PDAC-infiltrating T cells. γδ T cells encompass two major cytotoxic subtypes: the Vδ1 subtype that is mainly intra-epithelial and the Vγ9Vδ2 subtype which accounts for 1–10% of human circulating T lymphocytes but also comprises a considerable intra-epithelial compartment. Vγ9Vδ2 T cells can migrate towards tumors and are found within various human solid tumors. The Vγ9Vδ2 T cell receptor (TCR) senses phosphoAntigen, a metabolite of the mevalonate pathway of cholesterol biosynthesis. The blockade of this pathway with pharmacological agents, namely amino-phosphonates, leads to an accumulation of phosphoAntigen in malignant cells, that triggers Vγ9Vδ2 T cells activation and their MHC-unrestricted cytotoxicity towards tumor cells. Although intratumor γδ T cells have been shown to display high cytotoxicity against PDAC ex vivo, this cytotoxicity has been suggested to be dampened in patients with PDAC. Further research is needed to fully understand the role of γδ T cells in PDAC and to develop effective therapeutic strategies targeting these cells.
thermore, recent studies have shown tumor-infiltrating γδ T cells to instead drive the progression of PDAC in mice6,21 by restraining αβ T cells activation. Therefore, novel strategies are necessary to counter these γδ T cells-dependent immune escape mechanisms and restore Vγ9Vδ2 T cells cytolytic functions in PDAC.

TCR agonists including BrHpp (a synthetic phosphoAntigen) and aminobisphosphonates such as Zoledronate, are able to enhance Vγ9Vδ2 T cell anti-tumor functions and to increase the survival of PDAC cell line-xenograft mice.25 In this regard, the Butyrophilin3 A (BTN3A, CD277) subfamily through its TCR-mediated sensing of phosphoAntigens, has been shown to be a critical determinant in the recognition of human tumors by Vγ9Vδ2 T cells.23-25 The BTN3A subfamily belongs to the B7 family of costimulatory molecules and is composed of three isoforms (BTN3A1, BTN3A2 and BTN3A3).26 While expressed by both immune cells and tumor cells,24-27 BTN3A is more highly expressed in epithelial tumor tissues than in normal tissues, and is upregulated by tumor-associated soluble factors.26,28,29 Our team has demonstrated that targeting BTN3A molecules with antigen-anti-BTN3A 103.2 or 108.5 monoclonal antibodies (mAb) can completely abrogate Vγ9Vδ2 T cell mediated lysis of tumors.23,25 Conversely, the anti-BTN3A 20.1 mAb can strongly boost Vγ9Vδ2 T cells cytolytic function. Indeed, BTN3A targeting with this agonist mAb can sensitize tumor cell lines23 and resistant primary leukemic blasts to Vγ9Vδ2 T cells killing including when tested in a xenograft model.25

Together, these data have opened new perspectives in Vγ9Vδ2 T cells based-immunotherapies and shown the potential of BTN3A 20.1 mAb towards enhancing Vγ9Vδ2 T cell anti-tumor functions. In this study, we thus decided to investigate how BTN3A molecules might improve Vγ9Vδ2 T cell-based immunotherapy in PDAC.

**Results**

**BTN3A is overexpressed in human pancreatic tumors**

BTN3A expression in primary pancreatic tumors was addressed by comparing to peritumorally obtained control pancreatic tissue. Immunohistochemical analysis of PDAC Tissue Micro Arrays (TMA) confirmed BTN3A expression in all the tested tumor samples (n = 32) (Fig. 1A). By contrast, BTN3A expression was either absent or barely detectable in control pancreatic tissue. Immunofluorescence analysis also revealed prominent epithelial staining as determined by a co-localization of BTN3A and Keratin19 staining (Fig. 1B).

**BTN3A2 is the most abundant isoform expressed by PDAC**

BTN3A expression was first studied in cell lines that have been extensively used as PDAC models.30 These included PANC-1, MiaPACA2, and BxPc3 that have been shown to differ in their KRAS, P53, SMAD4 mutational status as well as Patu8902 and Patu8988 t that originate from primary and liver-metastatic PDAC and are respectively highly metastatic and poorly metastatic in mice.31,32 We observed BTN3A surface expression in all these pancreatic tumor cell lines, irrespective of their origin, mutational status or differentiation state (Fig. 2A, upper panel).

Secondly, we evaluated PDAC patient-derived xenograft cell lines that were derived from fresh tumors with various differentiation states and prognosis and established in our laboratory (n = 18).33 BTN3A was expressed in all of the tested patient-derived cell lines including one derived from a liver-metastasis (CRCM-14) (Fig. 2A lower panel).

As the available anti-BTN3A antibodies (used to confirm BTN3A surface expression) do not discriminate between the 3 BTN3A isoforms, we investigated BTN3A isoform expression at the transcript and protein levels by qRT-PCR and Western Blot. At the transcriptional level, we observed that all three isoforms were expressed with BTN3A2 the most abundant isoform in all of the tested pancreatic (Fig. 2B upper panel) and patient-derived xenograft-derived cell lines (Fig. 2B lower panel). At the protein level, BTN3A2 was also found to be the most abundant isoform (mean density quantification relative to loading control: 8.2 ± 6.2) when compared with BTN3A1 (1.3 ± 0.75) and BTN3A3 (3.7 ± 3.4) (Fig. 2C and Fig. 2B).

Collectively, these data demonstrated BTN3A surface expression in PDAC tumors with BTN3A2 isoform dominant ie. the isoform without the B30.2 cytoplasmic domain.

**The expression of BTN3A isoforms is modulated under hypoxia in PDAC**

We aimed to determine whether BTN3A isoform expression was modified under hypoxic stress in PANC-1 and MiaPACA2 cell lines. BTN3A1 and BTN3A2 transcript levels were higher under hypoxia compared to normoxia (fold increase of 2.78 [2.58–3.18]; P = 0.0294 and 1.64 [1.3–2.65]; P = 0.0265) (Fig. 3A). BTN3A isoform expression at the protein level was also assessed by Western Blot (Fig. 3B), in parallel with HIF1α expression as a control marker of hypoxia (Fig. 3B). BTN3A2 protein expression (36 kDa) was found to be higher under hypoxia in both PANC-1 (0.34 versus 0.22) (Fig. 3B) and a PDAC patient-derived xenograft (CRCM04) (0.45 versus 0.2) (Supplementary Fig. 1). In contrast, BTN3A1 and BTN3A3 could not be detected at their respective expected molecular weights of 57 and 65 kDa (Fig. 3B).

We next asked whether BTN3A surface expression was influenced by hypoxia. Flow cytometry analysis showed global surface expression of BTN3A in both PANC-1 and a PDAC-patient-derived xenograft (CRCM04) to remain stable under hypoxia when tested in vitro (Fig. 3C). To test in vivo, we used a xenograft mouse model transplanted with human PDAC (CRCM05) and looked for BTN3A expression in pimonidazole-stained hypoxic regions. BTN3A was still expressed in the hypoxic region of the PDAC tumor in vivo (Fig. 3D). In summary, our data suggest that while hypoxic conditions preferably enhance expression of the BTN3A2 isoform, global surface expression of BTN3A remains stable.

**BTN3A expression is also tuned under nutrient starvation**

At the transcript level, the expression of the BTN3A1 and BTN3A2 isoforms were increased under nutrient starvation when compared to standard nutrient supply when examined in
the PANC-1 cell line (fold increase of 4.47 [4.44–4.77];
P = 0.0294 and 2.35 [2.2–2.51]; P = 0.0294 respectively) (Fig. 4A). To determine if this also translated to an increase in global expression at the membrane surface, we also assessed BTN3A expression by flow cytometry in PANC-1 and PDAC patient-derived xenograft-derived (CRCM04) cell lines cultured in basal condition i.e. standard media and nutrient supply (DMEM FCS10%) or under conditions of nutrient starvation (EBSS). As illustrated in Fig. 4B, surface expression of BTN3A was found to not significantly differ between the two conditions.

**BTN3A is shed under soluble form via a mechanism partly mediated by MMP**

The increased transcript level of BTN3A1 and BTN3A2 observed under nutrient starvation (Fig. 4A) was not associated with an overall increase in surface expression of BTN3A (Fig. 4B). We asked therefore whether MMP cleavage could participate in BTN3A regulation. BTN3A expression was assessed in the PANC-1 cell line cultured under basal or nutrient-starvation conditions in the presence or absence of TAPI-1, a broad MMP inhibitor. Under basal conditions, the addition of TAPI-1 resulted in a significantly higher surface expression of BTN3A (7 [5.5–8.8]) versus 10.7 [6.9–12] for untreated cells; P = 0.0123) (Fig. 4C). Similarly, under nutrient starvation conditions, TAPI-1 also significantly increased BTN3A expression (23.2 [16.6–34.7]) compared to untreated nutrient-starved cells (16.6 [10.9–26]; P = 0.0298) (Fig. 4D). These observations indirectly suggest that there is a perpetual BTN3A cleavage by MMP in the PANC-1 cell line irrespective of the culture conditions used.

To determine whether BTN3A is released by PANC-1 cells, we analyzed soluble BTN3A concentrations in recovered supernatants by ELISA. Under basal conditions, the concentrations of BTN3A molecules PANC-1 supernatants were found to be
significantly lower level in TAPI-1-treated cells (99.3 ± 27.11 pg/ml versus 81.83 ± 22.1 pg/ml for untreated, *P* = 0.0355) (Fig. 4E). Collectively therefore, our data indicates that BTN3A molecules are released from PANC-1 cells in a process involving MMP.

**BTN3A2 participates in Vγ9Vδ2 T cells anti-tumor functions towards PDAC**

The role played by BTN3A in the lysis of PDAC by Vγ9Vδ2 T cells was investigated. The lysis of PANC-1 cells by Vγ9Vδ2 T cells was found either to be to be enhanced (*P* = 0.0156) by BrHpp treatment and reversed by anti-BTN3A 108.5 mAb (*P* = 0.0313) (Fig. 5A). On the contrary, the anti-BTN3A 20.1 mAb significantly increased the lysis of PANC-1 cells (*P* = 0.0313) (Fig. 5B). BrHpp and 20.1 mAb treatment also sensitized BxPC3, Patu8902, Patu8988 t and CRCM04 to Vγ9Vδ2 T cell mediated lysis but had no effect on MiaPACA2 cells (Supplementary Fig. 2). These findings highlight a key role of BTN3A (when triggered by BrHpp or anti-BTN3A 20.1 mAb) in the enhancement of Vγ9Vδ2 T cell lysis of all of the most poorly-sensitive PDAC cell lines except for MiaPACA2.

The role of BTN3A2 in Vγ9Vδ2 T cell anti-tumor function was also assessed by measuring Vγ9Vδ2 T cell degranulation.
and T_{11} cytokine production towards wild type BxPc3 or CrispR-Cas9 BTN3A2 invalidated-BxPc3 cell lines. Vγ9Vδ2 T cell degranulation (Fig. 5C) and the production of TNFα (Fig. 5D) and IFNγ (Fig. 5E) were significantly lower towards the BTN3A2 knockout cell line treated with anti-BTN3A 20.1 mAb, BrHpp or aminobisphosphonate Zoledronate (ZOL), than towards wild-type BxPc3 cell line. These data were consistent with the role of BTN3A2 in Vγ9Vδ2 T cell anti-tumor functions towards PDAC.

**BTN3A-dependent anti-tumor functions of Vγ9Vδ2 T cells are preserved under hypoxia**

We assessed whether hypoxia could affect BTN3A mediated anti-tumor functions of expanded Vγ9Vδ2 T cells from healthy donors. Treatment with the anti-BTN3A agonist 20.1 mAb was associated with a higher Vγ9Vδ2 T cells degranulation capability as determined by CD107 a/b expression (p = 0.0313) (Fig. 5F), and a greater production of IFNγ (p = 0.0313) (Fig. 5G) and TNFα (p = 0.0313) (Fig. 5H) towards PANC-1 cell line under both normoxic and hypoxic conditions. Treatment with BrHpp also significantly increased degranulation (Fig. 5F), and production of IFNγ (Fig. 5G) and TNFα (Fig. 5H) by Vγ9Vδ2 T cells towards PANC-1. These anti-tumor functions of BrHpp-treated Vγ9Vδ2 T cells were conserved under hypoxia (Fig. 5F–H) and significantly abrogated by anti-BTN3A 108.5 antagonist mAb (P = 0.0313)

Collectively, these data demonstrated the ability of anti-BTN3A 20.1 mAb to boost Vγ9Vδ2 T cell anti-tumor functions even under hypoxic conditions.

**BTN3A expression in human primary pancreatic tumors is associated with invasiveness**

Immunohistochemistry was used in order to determine whether BTN3A was differentially expressed within PDAC tumors. In PDAC inflammatory tissue micro arrays (n = 34), it was first noted that the percentage of BTN3A staining was significantly higher in the center than in the periphery of the PDAC tumors (5.62 [3.87–7.81]; (Dn 23)) when compared with patients devoid of lymph node involvement (N0) (2.73 [1.12–4.84]; (Dn 9); P = 0.0036) (Fig. 6A, left panel) in PDAC patients. Second, the percentage of BTN3A staining was found to be significantly higher in a group of patients with lymph node involvement (N1) (5.49 [2.87–7.77]; (Dn 23)) when compared with patients devoid of lymph node involvement (N0) (2.73 [1.12–4.84]; (Dn 9); P = 0.006) (Fig. 6A, right panel).

The level of BTN3A surface expression in patient-derived xenograft-derived cell lines was also assessed by flow cytometry. Two different groups of patients were segregated as previously reported (33): 1) a short-term survival group with poorly differentiated tumors with an overall survival less than 8 months and 2) a long-term survival with moderately/well differentiated tumors and an overall survival greater than 8 months (Supplementary Fig. 3). We observed that BTN3A expression
expressed as Median Fluorescence Intensity, was significantly higher in patients with poorly differentiated tumors and a poor prognosis when compared to patients in the long-term survival group (4057 [2867–7203] versus 2472 [976–3660]; \( P = 0.0441 \)) (Fig. 6B). In addition, the available data from TCGA database revealed that patients with higher BTN3A2 gene expression (i.e., higher than the median expression of the group; \( n = 85 \)) had lower overall median survival time than patient with lower BTN3A2 gene expression (\( n = 85 \)) (596 days versus 634 days; Hazard Ratio = 1.37 [1.04–1.81]; \( P = 0.025 \)) (Fig. 6C).

Altogether these data indicate an association of BTN3A expression with tumor progression, and in particular, with poorly differentiated tumors from PDAC patients who exhibited short-term survival.

**Soluble BTN3A and BTN3A1 concentration is a prognostic marker in PDAC patients**

As BTN3A was found as a released soluble form in pancreatic tumor cell line supernatant, we investigated whether soluble BTN3A was present in plasma samples taken from PDAC patients. We first evaluated whether soluble BTN3A1 concentrations obtained with a “BTN3A1-specific” dosage correlated with concentrations obtained with a “pan-BTN3A” dosage. We found a significant positive correlation between soluble BTN3A and soluble BTN3A1 concentrations observed in patients with Chronic Calcifying Pancreatitis (CCP) and Intraductal Papillary Mucinous Neoplasm (IPMN). The highest median concentration was observed in PDAC patients (1.78 ng/ml [1.03–3.28]) which was significantly higher than that observed in healthy donors (1.17 ng/ml [0.79–1.7]; \( P = 0.036 \)) (Fig. 6E). With respect to the overall survival of patients with PDAC, soluble BTN3A and BTN3A1 concentrations greater than 8 ng/ml (Fig. 6F) and 6 ng/ml respectively, were associated with a decreased overall survival (Fig. 6G). Altogether these data show the potential of soluble BTN3A and BTN3A1 as biomarkers that reflect the progression and prognosis of PDAC.

**Discussion**

The identification of novel immunotherapeutic targets while taking into account the specific microenvironment of PDAC is
of great concern. We report that the BTN3A subfamily is stress-regulated in PDAC tumors and shed by these cells under basal and nutrient-deprived conditions. We also demonstrate a critical role of BTN3A in mediating Vγ9Vδ2 T cells cytolytic functions against PDAC that is strongly enhanced by the agonist anti-BTN3A 20.1 mAb, even under conditions of hypoxia. Strikingly, we provide evidence that high levels of BTN3A expression in tissues and soluble BTN3A in plasma are prognostic markers in patients with PDAC.

BTN3A expression has rarely been investigated in the primary tumor context. Based on the analysis of human primary tumor samples and novel patient-derived xenografts, we have now established that BTN3A overexpression and a dominant expression of the BTN3A2 isoform is strongly associated with a poor prognosis, in accordance with what was recently described in primary leukemic blasts and in gastric cancer. In this line, the overexpression of BTN3A2 gene was associated with an increased proliferation and invasion of gastric cancer cell lines.

We show here that BTN3A2 is involved in phosphoAntigen-mediated Vγ9Vδ2 T cells activation towards PDAC. Indeed, the BTN3A subfamily including BTN3A2 has been shown to play a key role in mediating Vγ9Vδ2 T cells sensing of phosphoAntigen-containing tumor cell lines and primary leukemic blasts. Of note, binding of phosphoAntigen by the B30.2 intracellular domain of BTN3A1 has been demonstrated to be critical in this process. As a receptor that is devoid of an intracellular domain but can negatively regulate NK cells, it has previously been suggested that BTN3A2 may function as a decoy receptor via the binding of a putative ligand. Hence, we
could postulate that the higher level of expression of the BTN3A2 isoform compared to BTN3A1 may facilitate tumor immune escape mechanisms that lead to Vγ9Vδ2 T cells exhaustion and/or fail to activate Vγ9Vδ2 T cells in the absence of PAg.

Here, the expression of BTN3A1 and BTN3A2 was higher under stress condition, whereas BTN3A surface expression remained stable. This indicates a tight regulation of membrane BTN3A expression that might occur through the intracellular retention of BTN3A1 and BTN3A2 in the endoplasmic reticulum due to the presence of canonical ER retention/retrieval signals in their intracellular domains (Vantouroux et al., γ6 T cell conference 2016) or via BTN3A isoforms shedding. Accordingly, we observed soluble BTN3A isoforms including soluble BTN3A1 in the supernatants of pancreatic cell lines and in the plasma of PDAC patients. In addition, we showed that BTN3A shedding occurred in manner that is in part MMP-dependent, similar to that previously described for the NKG2D ligands MICA/B. We can assume that this increased release might result from enhanced MMP activity and BTN3A expression in PDAC patients. Indeed, both levels of soluble BTN3A and of BTN3A surface expression were associated with a poor prognosis of PDAC patients. Conversely, in patient with inflammatory or non-malignant pancreatic aggression such as chronic calcifying pancreatitis and intraductal papillary mucinous neoplasm, soluble BTN3A1 levels were not different from those found in healthy donors. This suggests that BTN3A1 upregulation might be a specific feature of PDAC associated inflammation.
The present study also confirms BTN3A as a promising therapeutic target: the agonist anti-BTN3A 20.1 mAb was shown to be a potent tool for boosting Vγ9Vδ2 T cell anti-tumor functions against PDAC. BTN3A triggering by the 20.1 mAb occurs mainly through the induction of extra-cellular conformational changes in BTN3A molecules of target cells, resulting in the induction of Vγ9Vδ2 T cell activation.23,39 Interestingly, the anti-BTN3A 20.1 mAb can separately trigger each of the three BTN3A isoforms including BTN3A2.23,39 Hence, the dominant expression of BTN3A2 found in tumors does not preclude the triggering of BTN3A molecules by the agonist 20.1 mAb and the effective activation of Vγ9Vδ2 T cells. Indeed, the anti-BTN3A 20.1 mAb was able to effectively enhance the lysis of various pancreatic cell lines including a novel aggressive patient-derived xenograft cell line. Nevertheless, BTN3A triggering fails to restore the sensitization of MiaPACA2 cell line illustrating the heterogeneous intrinsic sensitivity of pancreatic tumors, partly due to the lack of expression of the adhesion molecule ICAM-1 in this cell line.40

The tumor-induced exhaustion of Vγ9Vδ2 T cells in the PDAC microenvironment has been recently suggested.6 Hence, the 20.1 mAb could be of high therapeutic interest to both restore the cytotoxic functions of intratumoral Vγ9Vδ2 T cells and prevent the exhaustion of adoptively transferred Vγ9Vδ2 T cells. By way of support, we have shown that the agonist anti-BTN3A 20.1 is able to sustain the cytolytic functions of Vγ9Vδ2 T cells towards primary leukemic blasts resulting in their clearance from the bone marrow.25 In addition, this agonist effect on Vγ9Vδ2 T cells anti-tumor function was also maintained under hypoxia conditions, further underscoring its potential as a potent therapeutic tool that can overcome the stress-related characteristics of the PDAC microenvironment.

In conclusion, we have established that BTN3A expression is stress regulated and associated with pancreatic tumor prognosis, and might constitute an immune escape mechanism against Vγ9Vδ2 T cells recognition. However, BTN3A targeting with agonist mAb allows for the sensitization of PDAC to Vγ9Vδ2 T cells lysis even under conditions of hypoxia. Altogether these results underscore a promising pathway to explore in order to improve immunotherapeutic combinatorial strategies to treat PDAC.

Methods

Patients

Thirty-four PDAC samples were formalin-fixed surgical specimens obtained from the Pathology Department of Aix-Marseille University. Demographic data, lymph node status and overall survival corresponding to the length of time from the date of diagnosis of these patients is detailed in Supplementary Table 1.

Plasmas from PDAC patients (n = 67), Chronic Calcific Pancreatitis (n = 12), Intra Papillary Mucinous Neoplasms (n = 8) and Healthy control subjects (n = 23) were collected and provided by Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Barcelona.

Demographic data, TNM status and overall survival corresponding to the length of time from the date of diagnosis of these patients are provided in Supplementary Table 2. Healthy pancreatic specimens were taken from peritumoral region during surgery (tissue collection: DC-2013-1857).

Xenograft murine model

Mice were home-bred and maintained under pathogen-free conditions. All animal procedures were in accordance with protocols approved by the local Committee for Animal Experiments.

Patient-derived xenograft murine models were established as previously described.41 Briefly, patient-derived pancreatic tumor pieces (1 mm3) were embedded in Matrigel before being s.c implanted into flank of adult male Swiss nude Mice (Charles River laboratories), carried out under isoflurane anesthesia. Tumors were measured weekly with a caliper until tumor volume reached 1mm3. At 4 h after intratumoral injection of pimonidazole hydrochloride, pieces of tumor were removed fixed in 4% (wt/vol) formaldehyde or frozen in cold isopentane for further analysis.

Tissue microarrays (TMAs)

The procedure for construction of TMAs was as previously described.42,43 Briefly, cores were punched from the selected paraffin blocks and distributed in new blocks, with 2 cores of 0.6-mm diameter, one from the periphery (P) and one from the center of each tumor (T). TMA serial tissue sections were prepared 24 hours before immunohistochemical processing and stored at 4°C. The dilution of each antibody was determined by pre-screening on the full 4-μm-thick sections before use on TMA sections. The immunoperoxidase procedures were performed using an automated Ventana BenchMark XT autostainer. Measurements of immunoprecipitate densitometry in cores were made for each marker in an individual core after digitization and “cropping” of microscopic images as previously reported.42,43

Immunohistochemistry

Pancreatic sections were fixed in 4% paraformaldehyde and paraffin embedded. Immunohistochemistry was performed using standard procedures. Sections were stained with anti-BTN3A mAb (clone 103.2).

Hypoxic regions in PDAC were revealed using the Hypoxyprobe-1 Plus kit (Hypoxyprobe). Quenching of endogenous peroxidase activity by 3% (vol/vol) H2 O2 was followed by an antigen retrieval step (10 mM sodium citrate, pH 6, 55°C). Finally, sections were incubated with FITC-conjugated anti-pimonidazole monoclonal antibody (1:400, Hypoxyprobe) followed by an incubation with HRP-conjugated anti-FITC antibody (1:100, Hypoxyprobe). Peroxidase activity was revealed using liquid-Diaminobenzidine+ substrate chromogen system (Dako). Counterstaining with Mayer hematoxylin was followed by a bluing step in 0.1% sodium bicarbonate buffer, before final dehydration, clearance, and mounting of the sections.
**Confocal microscopy**

Ten-micrometer cryosections of pancreatic tissue were dried and fixed with acetone. After nonspecific binding site blockade with 3% bovine serum albumin, 10% fetal calf serum, and 10% goat serum for 30 minutes, tissue sections were labeled 1 hour at room temperature with primary antibodies BTN3A (clone 103.2) and keratin 19 (abnova (clinisciences), Nanterre, France), followed by incubation for 30 minutes at room temperature with secondary antibodies (Alexa Fluor 488 and 568 (Invitrogen, Cergy Pontoise, France)) and SYTOX Blue when nuclei staining was required. Slides were mounted in ProLong Gold (Invitrogen, Cergy Pontoise, France) and observed with a Zeiss LSM 510 confocal microscope. Images were analyzed using Adobe Photoshop 7.0.

**Pancreatic cell lines and culture system**

MiaPACA2, PANC-1, and BxPC-3 cells were obtained from the American Type Culture Collection. Patu8902 and Patu8988 were obtained from the Leibniz Institute DSMZ-German Collection of microorganisms and cell cultures. Patient-derived xenograft-derived cell lines were established as previously described.33 All cell lines were periodically tested for Mycoplasma contamination and were Mycoplasma-Free. Pancreatic cell lines and culture systems were maintained in Dulbecco’s modified Eagle’s medium (DMEM) (Invitrogen) supplemented with 10% FCS at 37°C with 5% CO2. To avoid any supplementary stress, all media were preheated at 37°C before rinsing or changing media. Nutrient starvation was obtained by cultivating cells with Earle’s Balanced Salt Solution (EBSS) (Ref# 24010-043). Hypoxia experiments were carried out using C-Shuttle Glove Box coupled hypoxia chamber (BioSpherix).

**Reagents and antibodies**

BrHpp and Zoledronate (ZOL) were obtained from Innate Pharma (Marseille, France) and Novartis (United Kingdom) respectively. Recombinant human (Rh) IL-2 was obtained from BD Biosciences (San Jose, CA, USA) and TAPI-1 from Peptides International (Louisville, KY, USA). The mAbs used for functional experiments and cytometry are listed in Supplementary Table 3.

**Vγ9Vδ2 T cells expansion**

Effector γδ T cells were established and maintained as previously described.44 Peripheral Blood Mononuclear Cells (PBMCs) from healthy donors were provided by the local Blood Bank (EFS) and isolated by density gradient centrifugation. PBMCs were stimulated with ZOL (1 μM) or BrHpp (3 μM) and rhIL-2 (200 IU/ml) at Day 0. From Day 5, rhIL-2 was renewed every two days and cells were kept at 1.5 × 10⁶/ml for 15 days. The purity of γδ T cells was determined to be greater than 80%.

**HEKShBTN3A**

BTN3A Knock-down HEK293FT cells (sh#284; clone#30) were cultured and transfected with BTN3A1, BTN3A2, BTN3A3 mutated cDNA-containing plasmids, as described.23

**CRISPR plasmid construction**

CRISPR plasmid construction was adapted from the protocol previously described.43 pSpCas9(2BB)-2 A-GFP (PX458) was a gift from Feng Zhang (Addgene plasmid # 48138). PX458 plasmid was linearized using BbsI (37°C, one hour digestion). sgRNA targeting the sequence 5’-GAGTGAGGAGCTGGACAAAGG-3’ within the signal peptide of BTN3A2 (Third exon) was devised manually. The guide oligonucleotides (oligon) targeting BTN3A2 were purchased from Invitrogen:

- Top strand oligon was: 5’-CACCGAGTGACAGCTGGACAAAGG-3’ and Bottom strand oligon was: 5’-AAACCTTGTCCAGCTGCTACTC-3’. The guide oligon for the top and bottom strand contain overhangs for ligation into the pair of BbsI sites in PX458 (in bold case). The sgRNA oligon were annealed in a thermocycler by using the following parameters: 95°C for 5 min; ramp down to 85°C at 2°C/s, then ramp down to 25°C at 0.1°C/s. sgRNA oligon were cloned into PX458 plasmid by incubating them with PX458 and T4 ligase (New England Biolabs) during one hour at 37°C. Then, 20 μl of E. Coli DH5-α strain (from Invitrogen) were transformed with 2 μl ligation product and immediately seeded on LB-agar ampicillin plates (50 μg/ml). Primary screening of clones with the correct insertion was performed with a BbsI/AgeI double digestion of colonies’ mini-preps. Confirmation of positive clones carrying the correct insertion was assessed by Sanger sequencing (GATC Biotech).

**BxPC-3 transfection and clonal isolation**

BxPC-3 cells were seeded the day before transfection at 70% confluency. BxPC-3 cells were then transfected with FuGENE® HD (Promega®) at a 4:1 ratio (Reagent/DNA ratio). 48 hours after transfection, the BxPC-3 clones which expressed the highest GFP levels were sorted and isolated by FACS (BD FACSAriaTM II). Afterwards, 250 GFP+ cells were cultured in ClonaCell™-TCS Medium (StemCell™ Technologies) (Hydroximethylcellulose-based semisolid medium) with 1% Penicillin/Streptomycin, 20% RPMI 1640 with 10% FBS in order to allow the formation of monoclonal colonies. Thirty days later, BxPC-3 colonies were manually picked from the semisolid medium plate then expanded and viably frozen to allow for functional experiments.

**Genomic PCR and sequence analysis of BxPC-3 CRISPR clones**

Primers PCR and sequence analysis of BxPC-3 CRISPR clones

Primers PCR and sequence analysis of BxPC-3 CRISPR clones

> Primes PCR and sequence analysis of BxPC-3 CRISPR clones

---

**HEKShBTN3A**

BTN3A Knock-down HEK293FT cells (sh#284; clone#30) were cultured and transfected with BTN3A1, BTN3A2, BTN3A3 mutated cDNA-containing plasmids, as described.23

**CRISPR plasmid construction**

CRISPR plasmid construction was adapted from the protocol previously described.43 pSpCas9(2BB)-2 A-GFP (PX458) was a gift from Feng Zhang (Addgene plasmid # 48138). PX458 plasmid was linearized using BbsI (37°C, one hour digestion). sgRNA targeting the sequence 5’-GAGTGAGGAGCTGGACAAAGG-3’ within the signal peptide of BTN3A2 (Third exon) was devised manually. The guide oligonucleotides (oligon) targeting BTN3A2 were purchased from Invitrogen:

- Top strand oligon was: 5’-CACCGAGTGACAGCTGGACAAAGG-3’ and Bottom strand oligon was: 5’-AAACCTTGTCCAGCTGCTACTC-3’. The guide oligon for the top and bottom strand contain overhangs for ligation into the pair of BbsI sites in PX458 (in bold case). The sgRNA oligon were annealed in a thermocycler by using the following parameters: 95°C for 5 min; ramp down to 85°C at 2°C/s, then ramp down to 25°C at 0.1°C/s. sgRNA oligon were cloned into PX458 plasmid by incubating them with PX458 and T4 ligase (New England Biolabs) during one hour at 37°C. Then, 20 μl of E. Coli DH5-α strain (from Invitrogen) were transformed with 2 μl ligation product and immediately seeded on LB-agar ampicillin plates (50 μg/ml). Primary screening of clones with the correct insertion was performed with a BbsI/AgeI double digestion of colonies’ mini-preps. Confirmation of positive clones carrying the correct insertion was assessed by Sanger sequencing (GATC Biotech).

**BxPC-3 transfection and clonal isolation**

BxPC-3 cells were seeded the day before transfection at 70% confluency. BxPC-3 cells were then transfected with FuGENE® HD (Promega®) at a 4:1 ratio (Reagent/DNA ratio). 48 hours after transfection, the BxPC-3 clones which expressed the highest GFP levels were sorted and isolated by FACS (BD FACSAriaTM II). Afterwards, 250 GFP+ cells were cultured in ClonaCell™-TCS Medium (StemCell™ Technologies) (Hydroximethylcellulose-based semisolid medium) with 1% Penicillin/Streptomycin, 20% RPMI 1640 with 10% FBS in order to allow the formation of monoclonal colonies. Thirty days later, BxPC-3 colonies were manually picked from the semisolid medium plate then expanded and viably frozen to allow for functional experiments.
Once obtained, the PCR products were purified with Nucleospin® Gel and PCR Clean-up (MACHEREY-NAGEL GmbH & Co). DNA concentration of purified PCR products was measured with Nanodrop® ND-1000 (ThermoFisher™ Scientific). Sanger sequencing of purified PCR products was subsequently performed (GATC Biotech). Quality of sequencing results was visually assessed with FinchTV (Geospiza™). DNA sequences were aligned one to each other with the multiple sequence alignment tool MUSCLE (EMBL-EBI). If two or more sequences were observed from the CRISPR plasmid cut site for one purified PCR product, each allelic sequence was then cloned analyzing the PCR pool into pCR®-Blunt plasmid (ThermoFisher™ Scientific).

**Purified PCR products cloning into pCR®-Blunt plasmid and allelic sequencing**

pCR®-Blunt plasmid was linearized performing a digestion with Stul during two hours at 37°C. Then, the digestion product was run on a 2% agarose gel. The 3.5 Kb band was extracted with StuI during two hours at 37°C. The digestion product was subsequently performed (GATC Biotech). Quality of sequencing results was visually assessed with FinchTV (Geospiza™). DNA sequences were aligned one to each other with the multiple sequence alignment tool MUSCLE (EMBL-EBI). If two or more sequences were observed from the CRISPR plasmid cut site for one purified PCR product, each allelic sequence was then analyzed cloning into pCR®-Blunt plasmid incubating them in the presence of T4 ligase at room temperature during two hours. Afterwards, 20 µl of E. Coli DH5-α strain (from Invitrogen) were transformed with 2 µl ligation product, overnight during one hour in S.O.C. medium (Invitrogen) and seeded on LB-agar Kanamycin plates (50 µg/ml). The day after, colonies were picked and cultured in 2 ml LB kanamycin overnight. Then, plasmid DNA was isolated from miniprep with Nucleospin® Plasmid (MACHEREY-NAGEL GmbH & Co). Plasmids concentrations was measured with Nanodrop® ND-1000 (ThermoFisher™ Scientific). Sanger sequencing of purified PCR products was subsequently performed (GATC Biotech). Quality of sequencing results was visually assessed with FinchTV (Geospiza™). DNA sequences were aligned one to each other with the multiple sequence alignment tool MUSCLE (EMBL-EBI).

**Generation of anti-human BTN3A mAbs and BTN3A-Fc**

BTN3A1-Fc, BTN3A2-Fc and BTN3A3-Fc and anti-BTN3A mAbs clones 20.1, 103.2 and 108.5 were generated as previously described.26 Clones 20.1 and 103.2 were further labeled for cytometry using Alexa Fluor® 647 Protein Labeling Kit (Life Technologies).

**Determination of BTN3A isoforms expression by quantitative RT-PCR (qRT-PCR) in Wild Type PDAC cell lines**

RNA from cells was prepared using Trizol (Invitrogen, Cergy Pontoise, France) according to the manufacturer’s instructions. RNA concentration was determined by absorption and RNA integrity was checked on RNA Nano chips (Agilent, Santa Clara, CA). Reverse transcription (RT) reactions were performed on 1 µg of total RNA using Go Script (Promega, Madison, WI) according to the manufacturer’s protocol.

qPCR reactions were run in duplicate on two independent cDNA preparations. qPCR was performed in Stratagene MX3005P machine (Agilent, Santa Clara, CA) using TaqMan® Universal Master Mix II, with UNG (Applied biosystem (Invitrogen), Cergy Pontoise, France). The crossing point (Cp), defined as the point at which the fluorescence rises appreciably above the background fluorescence, was determined for each transcript. The 2ΔΔCp method was used to analyze the relative gene expression. The Peptidylprolyl Isomerase A (PPIA) gene (ref 4331182) was chosen as control. Three BTN3A isoforms are measured: BTN3A1 (Hs01063368_m1), BTN3A2 (Hs00389328_m1) and BTN3A3 (Hs00757230_m1).

**Transcriptomic analysis**

Transcriptomic analysis was performed by using the software PROGgeneV2. This tool allows us to analyze TCGA public databases according to different survival measurements as overall survival.46 The pancreatic cancer TCGA database pools 170 patients and clusters by high and low expression of selected gene expression (compared to the global median expression) in order to create Kaplan Meier overall survival curves compared using LogRank Test.

**Western blot**

Ten cm-culture dishes were placed on ice, washed in PBS and cells were dissociated and lysed in 250 µl of ice-cold HNTG buffer (50 mM HEPES pH 7, 50 mM NaF, 1 mM EGTA, 150 mM NaCl, 1% Triton X-100, 10% glycerol, and 1.5 mM MgCl2) in the presence of protease inhibitors (Roche Applied Science) and 100 µM Na3VO4. Protein quantification in all cell lysates was performed according to the manufacturer (Biorad quantification kit). Proteins were resolved by SDS-PAGE 10%, followed by western blotting. Primary antibodies (anti-BTN3A 20.1 mAb, anti-HIF1α (BD Biosciences), anti-γ tubulin, anti-Grb2 (SantaCruz technology)) were detected with peroxidase-conjugated anti-mouse IgG1 and anti-rabbit IgG antibody (Jackson Laboratory) and immunoreactive bands were confirmed using enhanced chemiluminescent reagents (Pierce). Quantification of the density of immunoreactive bands was performed using the ImageJ program.

**Flow cytometry**

2 × 10^6 PBMC were washed in PBS (Cambrex Bio Science) and incubated at 4°C for 20 min with specified mAb. Following incubation and washing, samples were analyzed on LSRFortessa or FACS Canto II (Becton Dickinson) using DIVA software (BD bioscience, Mountain View, CA). For analysis of CD107 expression, γδ T cells were incubated at 37°C with target cells in the presence of anti-CD107a/b and Golgi stop with or without BrHpp, anti-BTN3A 20.1 mAb or anti-BTN3A 108.5 mAb in normoxia or hypoxia. When specified, the target cell was pretreated O/N with zoledronate (ZOL) 25 μM then washed before co-culture with γδ T cells. After 4 hours, cells were collected, washed in PBS and analyzed by flow cytometry. To study cytokine production, cells were further permeabilized with Permwash (BD bioscience) to allow intracellular staining with labeled antibodies.
Cytotoxic activity analysis

1 × 10^6 target cells were incubated with 20 μCi of ^51^Cr (Perkin-Elmer) for 60 minutes and mixed with effector cells in a Effector: Target (E:T) ratio of 30:1; 10:1; 1:1. After 4 hours of incubation at 37°C, 50 μl supernatant of each sample was transferred in LUMA plates and radioactivity was determined by a gamma counter. The percentage of spontaneous release / total – spontaneous release] × 100 and expressed as the mean of triplicate.

Enzyme linked immunosorbent assay (ELISA)

“Pan-BTN3A” and “BTN3A1-specific” sandwich ELISAs were conceived by Dynabio®. Were used as capture antibodies: 1/ anti-BTN3A mAb clone that recognizes the 3 BTN3A-Fc recombinant proteins i.e BTN3A1-Fc, BTN3A2-Fc and BTN3A3-Fc for “Pan-BTN3A” ELISA and 2/ anti-BTN3A mAb clone that only recognizes BTN3A1-Fc for “BTN3A1-specific” ELISA. Anti-BTN3A 103,2 μAb that recognizes the 3 BTN3A isoforms was biotinylated for detection of BTN3A isoforms. The efficiency of biotinylation was validated comparing to detection mAb used for Pancreatitis-Associated Protein (PAP) ELISA test (Dynabio®) and using recombinant BTN3A-Fc proteins. After blockade of the plate, supernatants of pancreatic cell lines, plasmas of patients or BTN3A1-Fc, BTN3A2-Fc and BTN3A3-Fc recombinant proteins used as standards were added. After repeated washes, biotinylated detection-anti-BTN3A mAb were added. Revelation was achieved with avidin-HRP. The optical density of each well was determined using a microplate reader set to 450 nm. The concentration of each BTN3A isoform was assessed following the standard curve obtained with BTN3A1-Fc protein.

Statistical analysis

Results are expressed as median ± interquartile range. Statistical analysis was performed using two-tailed paired t-test, Wilcoxon test, Mann–Whitney t test and Spearman correlation. P values < 0.05 were considered significant. Survival curves were compared using LogRank Test. Analyses were performed using GraphPad Prism program.

TMA statistical analysis

To identify differentially expressed biomarkers, ANOVA analysis was performed. Since TMA comprises 2 groups of PDAC patients staged N0 and N1, ANOVA analysis was followed by post hoc analysis with Tukey-Kramer test. Then, percentage of staining was compared between patients N0 and patients N1 using Mann-Whitney Test. The analysis was performed using NCSS software (Kaysville, Utah).

Study approval

Written informed consent was obtained from patients included in this study, in accordance with the Declaration of Helsinki. The study was approved by the local institutional review boards of the Institut-Paoli-Calmettes.

Competing financial interests

DO is founder of Imcheck Therapeutics.

Acknowledgments

We thank the CRCM animal core, cytometry and immunomonitoring facilities for their technical assistance. We acknowledge S.Just-Landi, S. Pastor, C.Bontemps, C. Kozaczyk and C.Pasero for technical support. We thank C.Allasia for TMA statistical analysis. We thank S.Hannify for commenting and editing the manuscript.

This study was supported by research grant from Fondation ARC to AB and CC, Fondation pour la Recherche Médicale to EF, Ligue contre le Cancer to JLB and Institut National du Cancer to ASC, ANR GDStress, Fondation pour la Recherche Médicale (FRMDEQ20140329534), Instituto de Salud Carlos III (PI13/02192, co-funded by FEDER-European Union). DO is senior member of Institut Universitaire de France. CIBEREHD is funded by the Instituto de Salud Carlos III.

Author contributions

AB designed research, performed experimental work, analyzed and interpreted data and wrote the manuscript. CL performed experimental work and analyzed data and contributed to draft the manuscript. EF, JLB, CC, ND designed, performed and analyzed ELISA and 2/anti-BTN3A mAb were added. Revelation was achieved with avidin-HRP. The optical density of each well was determined using a microplate reader set to 450 nm. The concentration of each BTN3A isoform was assessed following the standard curve obtained with BTN3A1-Fc protein.

Acknowledgments

We thank the CRCM animal core, cytometry and immunomonitoring facilities for their technical assistance. We acknowledge S.Just-Landi, S. Pastor, C.Bontemps, C. Kozaczyk and C.Pasero for technical support. We thank C.Allasia for TMA statistical analysis. We thank S.Hannify for commenting and editing the manuscript.

This study was supported by research grant from Fondation ARC to AB and CC, Fondation pour la Recherche Médicale to EF, Ligue contre le Cancer to JLB and Institut National du Cancer to ASC, ANR GDStress, Fondation pour la Recherche Médicale (FRMDEQ20140329534), Instituto de Salud Carlos III (PI13/02192, co-funded by FEDER-European Union). DO is senior member of Institut Universitaire de France. CIBEREHD is funded by the Instituto de Salud Carlos III.

Author contributions

AB designed research, performed experimental work, analyzed and interpreted data and wrote the manuscript. CL performed experimental work and analyzed data and contributed to draft the manuscript. EF, JLB, CC, ASC performed experimental work and analyzed data. ND designed research and provided PDX-derived cell lines. SC and MM contributed to the design of the project research. VS, EV, GM and MG provided patients samples and analyzed data. JCD designed, performed and analyzed ELISA test. DO and JLI designed research, contributed to the analysis and interpretation of data and to draft the manuscript.

ORCID

Juan-Luis Blazquez (http://orcid.org/0000-0003-1822-2237)
Giuseppe Montalto (http://orcid.org/0000-0002-8731-8577)

References

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66:7–30. [https://doi.org/10.3322/caac.21332]. PMID:26742998
2. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711–23. [https://doi.org/10.1056/NEJMoa1003466]. PMID:20525992
3. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366:2443–54. [https://doi.org/10.1056/NEJMoa1206900]. PMID:22658127
4. Farren MR, Mace TA, Geyer S, Mikhail K, Tahiri S, Ahsan D, Noonan AM, Villalona-Calero M, et al. Systemic immune activity predicts overall survival in treatment-naive patients with metastatic pancreatic cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2016;22:2565–74. [https://doi.org/10.1158/1078-0432.CCR-15-1732]
5. Diana A, Wang LM, D’Costa Z, Allen P, Azad A, Silva MA, Soon-awalla Z, Liu S, McKenna WG, Muschel RJ, et al. Prognostic value, localization and correlation of PD-1/PD-L1, CD8 and FOXP3 with the desmoplastic stroma in pancreatic ductal adenocarcinoma. Oncotarget. 2016;7(27):40992–1004. [https://doi.org/10.18632/oncotarget.10038]. PMID:27329602
6. Daley D, Zamirinis CP, Seifert L, Akkad N, Mohan N, Werba G, Barilla R, Torres-Hernandez A, Hundeyin M, Mani VR, et al. γδ T cells support pancreatic oncogenesis by restraining αβ T cell activation. Cell. 2016;166:1485–1499.e15. [https://doi.org/10.1016/j.cell.2016.07.046]. PMID:27569912
7. Chang Q, Jurisca I, Do T, Hedley DW. Hypoxia predicts aggressive growth and spontaneous metastasis formation from orthotopically grown primary xenografts of human pancreatic cancer. Cancer Res. 2011;71:3110–20. [https://doi.org/10.1158/0008-5472.CAN-10-4049]. PMID:21343390
8. Hamas M, Messiah J, Ziani L, Thierry J, Bouhria JH, Noman MZ, Chouaib F. Critical role of tumor microenvironment in shaping NK cell functions: implication of hypoxic stress. Front Immunol. 2015;6:482. [https://doi.org/10.3389/fimmu.2015.00482]. PMID:26441986
9. Noman MZ, Janji B, Kaminiska B, Van Moer K, Pierson S, Przanowski M, Buart S, Van Pelt J, Richon C, Hasmim M, Leleu N, Cordova A, Toia F, La Mendola C, Orlando V, Meraviglia S, Rinaldi Gober H-J, Kistowska M, Angman L, Jenimimmok, Mönkönnen J, Mönkönnen J, Li J, Kuball J, Adams EJ, Netzer S, et al. Key implication of CD277/butyrophilin-3 (BTN3A1) in cellular stress sensing by a major human γδ T-cell subset. Blood. 2012;120:2269–79. [https://doi.org/10.1182/blood-2012-05-430470]. PMID:22767497
10. Rhodes DA, Chen HC, Price AJ, Keeble AH, Davey MS, James LC, Eber M, Trousselet J. Activation of Human γδ T Cells by Cytosolic Interactions of BTN3A1 with Soluble Phosphoantigens and the Cytotoxic T-Cell Antigen. Cell. 2014;119:2359–72. [https://doi.org/10.1016/j.cell.2014.03.014]. PMID:24823639
11. Kabinet D, Wesch D, Pitters E, Zoller M. Characterization of tumor reactivity of human V γ 9V δ 2 gamma delta T cells in vitro and in SCID mice in vivo. J Immunol. 2004;173:6767–76. [https://doi.org/10.4049/jimmunol.173.11.6767]. PMID:15557170
12. Duconseil P, Gilabert M, Gayet O, Loncle C, Moutardier V, Turrini O, Kissmeyer-Nielsen A, von Lilienfeld-Toal M, Buchtin C, Cheli S, Scabini S, Romairone E, Catellani S, et al. Zoledronate induces dramatic expansion of γδ T cells-based immunotherapy in advanced melanoma patients. J Immunother. 2016;39:205–11. [https://doi.org/10.1007/s00255-016-0430-2]. PMID:27853633
13. Cotterill JA, Benelli R, Scabini S, Romairone E, Catellani S, et al. Zoledronate mediates malignant cell lysis by Vγ9Vδ2 T cells-based immunotherapy in advanced melanoma patients. J Immunother. 2016;39:205–11. [https://doi.org/10.1007/s00255-016-0430-2]. PMID:27853633
14. Harly C, Guillaume Y, Nedellec S, Peigno L, De Libero G. Expression of BTN3 molecules belonging to the B7 family expressed on CML lymphoid cells and in SCID mice in vivo. J Immunol. 2015;194:5:2390–9. [https://doi.org/10.1074/jimmunol.1401064]. PMID:25637025
15. Benyamine A, Le Roy A, Maimesser E, Gertner-Dardenne J, Castanier C, Orlanducci F, Poyyet L, Goubard A, Collette Y, Vey N, et al. BTN3A1 molecules considerably improve Vγ9Vδ2 T cells-based immunotherapy in acute myeloid leukemia. Oncoimmunology. 2016;5:e146843. [https://doi.org/10.1080/2162402X.2016.1169483]. PMID:27853633
16. Compte E, Pontarotti P, Collette Y, Lopez M, Olive D. Frontline: Characterization of BT3 molecules belonging to the B7 family expressed on immune cells. Eur J Immunol. 2004;34:2089–99. [https://doi.org/10.1002/eji.200425227]. PMID:15259006
17. de la Pege C, Marineau A, Bonza PK, Rahimi K, Cyr L, Labouiba I, Madore J, Delvoye N, Mes-Masson AM, Provencer DM, et al. BTN3A2 expression in epithelial ovarian cancer is associated with higher tumor infiltrating T cells and a better prognosis. PLoS One. 2012;7:e38541. [https://doi.org/10.1371/journal.pone.0038541]. PMID:22685580
18. Cubillos-Ruiz JR, Martinez D, Scarlett UK, Rutkowski MR, Nesbath YC, Campoescowe-Jacobs AL, Conejo-Garcia JR. CD277 is a negative co-stimulatory molecule universally expressed by ovarian cancer microenvironmental cells. Oncoarget. 2010;1:329–38. [https://doi.org/10.18632/oncotarget.165]. PMID:2113407
19. Zhu M, Yan C, Ren C, Huang X, Zhu X, Gu H, Wang M, Wang S, Gao Y, Ji Y, et al. Exome array analysis identifies variants in SPOC1 and BTN3A2 that affect risk for gastric cancer. Gastroenterology. 2017;152(8):2011–2021. [https://doi.org/10.1053/j.gastro.2017.02.017]. PubMed [Epub 2017 Feb 27]
20. Deer EL, Gonzalez-Hernandez J, Courson JD, Shea JE, Ntaga J, Scaife CL, Firpo MA, Mulvihill SJ. Phenotype and genotype of pancreatic cancer cell lines. Pancreas. 2010;39:425–35. [https://doi.org/10.1097/MPA.0b013e3181c15963]. PMID:20418756
21. Elsasser HP, Lehr U, Agricola B, Kern HF. Structural analysis of a new highly metastatic cell line PaTu 8902 from a primary human pancreatic adenocarcinoma. Virchows Arch B Cell Pathol Incl Mol Pathol. 1992;61:295–302. [https://doi.org/10.1007/BF02915113]. PMID:8287116
22. Benelli R, Scabini S, Romairone E, Catellani S, et al. Zoledronate mediates malignant cell lysis by Vγ9Vδ2 T cells-based immunotherapy in advanced melanoma patients. J Immunother. 2016;39:205–11. [https://doi.org/10.1007/s00255-016-0430-2]. PMID:27853633
23. Charpentier M, Auroux A, Diez E, Benounna J, Mosnier JF, Sco- tete E, Bonneville M, Joretue F. V γ 9 V δ 2 T cells response to colon carcinoma cells. J Immunol. 2005;175:5481–8. [https://doi.org/10.4049/jimmunol.175.8.5481]. PMID:16210656
24. Zocchi MR, Costa D, Venere O, de Nardis E, de Preiner C, Rizzuto R, Boni S, Marnell MJ, Zampino L, et al. A small molecule that activates the innate immune response and inhibits tumor cell growth in vivo. Cancer Res. 2011;71:5762–72. [https://doi.org/10.1158/0008-5472.CAN-10-3862]. PMID:21646473
25. Maren T, von Lilienfeld-Toal M, Buecher MW, Schmidt J, Schmitz J. MIC is elevated in the serum of patients with pancreatic carcinoma diminishing gemtuzumab T-cell cytotoxicity. Int J Cancer Int Cancer. 2006;119:2359–65. [https://doi.org/10.1002/ijc.21816]
26. McAllister F, Bailey JM, Alsina J, Nirschl CJ, Sharma R, Fan H, Ratti- gan Y, Roesser JC, Lankapalli RH, Zhang H, et al. Oncogenic Kras activates a hematopoietic-to-epithelial IL-17 signaling axis in preinvasive pancreatic neoplasia. Cell. 2014;157:621–37. [https://doi.org/10.1016/j.cell.2014.03.014]. PMID:24823639
27. Maren T, von Lilienfeld-Toal M, Buecher MW, Schmidt J, Schmitz J. MIC is elevated in the serum of patients with pancreatic carcinoma diminishing gemtuzumab T-cell cytotoxicity. Int J Cancer Int Cancer. 2006;119:2359–65. [https://doi.org/10.1002/ijc.21816]
28. McAllister F, Bailey JM, Alsina J, Nirschl CJ, Sharma R, Fan H, Rattigan Y, Roesser JC, Lankapalli RH, Zhang H, et al. Oncogenic Kras activates a hematopoietic-to-epithelial IL-17 signaling axis in preinvasive pancreatic neoplasia. Cell. 2014;157:621–37. [https://doi.org/10.1016/j.cell.2014.03.014]. PMID:24823639
B30.2 domain of butyrophilin 3A1 binds phosphoantigens to mediate activation of human Vγ9Vδ2 T cells. Immunity. 2014;40:490–500. PMID:24703779

37. Wang H, Henry O, Distefano MD, Wang YC, Rääikkönen J, Mönkkönen J, Tanaka Y, Morita CT. Butyrophilin 3A1 plays an essential role in prenyl pyrophosphate stimulation of human Vγ2Vδ2 T cells. J Immunol. 2013;191:1029–42. PMID:23833237

38. Messal N, Mamessier E, Sylvain A, Celis-Gutierrez J, Thibault M-L, Chetaille B, Firaguay G, Pastor S, Guillaume Y, Wang Q, et al. Differential role for CD277 as a co-regulator of the immune signal in T and NK cells. Eur J Immunol. 2011;41:3443–54. PMID:21918970

39. Palakodeti A, Sandstrom A, Sundaresan L, Harly C, Nedellec S, Olive D, Scotet E, Bonneville M, Adams EJ. The molecular basis for modulation of human Vγ9Vδ2 T cell responses by CD277/butyrophilin-3 (BTN3A)-specific antibodies. J Biol Chem. 2012;287:32780–90. PMID:22846996

40. Liu Z, Guo B, Lopez RD. Expression of intercellular adhesion molecule (ICAM)-1 or ICAM-2 is critical in determining sensitivity of pancreatic cancer cells to cytolysis by human gammadelta-T cells: implications in the design of gammadelta-T-cell-based immunotherapies for pancreatic cancer. J Gastroenterol Hepatol. 2009;24:900–11. PMID:19175829

41. Guillamond F, Leca J, Olivares O, Lavaut MN, Vital N, Berthezene P, Dusetti NJ, Loncle C, Calvo E, Turrini O, et al. Strengthened glycolysis under hypoxia supports tumor symbiosis and hexosamine biosynthesis in pancreatic adenocarcinoma. Proc Natl Acad Sci U S A. 2013;110:3919–24. PMID:23407165

42. Charpin C, Tavassoli F, Secq V, Giusiano S, Villaret J, Garcia S, Birnbaum D, Bonnier P, Lavaut MN, Boubli L, et al. Validation of an immunohistochemical signature predictive of 8-year outcome for patients with breast carcinoma. Int J Cancer J Int Cancer. 2012;131: E236–243.

43. Giusiano S, Secq V, Carcopino X, Carpentier S, Andrac L, Lavaut MN, Allasia C, Bonnier P, Iovanna JL, Garcia S, et al. Immunohistochemical profiling of node negative breast carcinomas allows prediction of metastatic risk. Int J Onco. 2010;36:889–98. PMID:20198333

44. Gertner J, Wiedemann A, Poupot M, Fournié JJ. Human gammadelta T lymphocytes strip and kill tumor cells simultaneously. Immunol Lett. 2007;110:42–53. [https://doi.org/10.1016/j.imlet.2007.03.002]. PMID:17451812

45. Ran FA, Hsu PD, Wright J, Agarwala V, Scott DA, Zhang F. Genome engineering using the CRISPR-Cas9 system. Nat Protoc. 2013;8:308–308. [https://doi.org/10.1038/nprot.2013.143]. PMID:24157548

46. Goswami CP, Nakshatri H. PROGgene: gene expression based survival analysis web application for multiple cancers. J Clin Bioinforma. 2013;3:22. [https://doi.org/10.1186/2043-9113-3-22]. PMID:24165311